den 18 december 2015

Important legal information

AstraZeneca, U.K.‘s second largest drugmaker, will pay USD 4 billion for 55 percent stake in Acerta Pharma BV, a Dutch pharmaceutical company.

Acerta Pharma developed a potential blockbuster cancer medicine, which induced AstraZeneca to pay USD 2.5 billion upfront and another USD 1.5 billion when “Acalabrutinib” is approved by a regulator.

AstraZeneca’s stock has dropped 3 percent this year, compared with a 9 percent gain in the Bloomberg Europe Pharmaceutical Index. However, the latest news induced an increase of 1.3 percent in behalf of AstraZeneca. Analysts at Credit Suisse Group AG wrote that AstraZeneca’s earnings will be curtailed until 2018 through the Acerta deal. Nevertheless they also mentioned that it looks very reasonable for AstraZeneca to invest overall USD 7 billion in the process of approval, while thinking of AbbVie bought Imbruvica’s developer “Pharmacyclics” for USD 21 billion.

AstraZeneca’s Chief Executive Officer, Pascal Soriot, is optimistic and announces that “Acalabrutinib” may garner peak annual sales of more than USD 5 billion. The agreement includes options to buy the rest of Acerta for about USD 3 billion. The attendance to invest a several amounts of money in the approval of a new cancer medicine and to invest even more in Acerta sends a certain signal to the biotechnology sector. Big investments could have influence on the biotechnology markets, but also on further competitors such as Amgen, Biogen, Gilead and Celgene. However, the further development remains to be seen.



2023-01-28 08:32:50